Interestingly, AR-V7, as AR splice variant in prostate cancer, is the most extensively researched among tumors and circulating tumor DNAs (103); it is widely accepted that monitoring and inhibiting AR-V7 is a clinical priority in prostate cancer treatment (104). The gene discussed is AR; the disease is prostate carcinoma.